BiotechTube

Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsule

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioequivalence

Conditions

Bioequivalence

Trial Timeline

Feb 25, 2021 → May 10, 2021

NCT ID
NCT04768985

About Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsule

Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsule is a phase 1 stage product being developed by AstraZeneca for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT04768985. Target conditions include Bioequivalence.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04768985Phase 1Completed

Competing Products

20 competing products in Bioequivalence

See all competitors
ProductCompanyStageHype Score
Bupropion HCl MR tablets 300mgAlembic PharmaceuticalsPhase 1
32
Fingolimod 0.5 mg capsules- Test drugAlembic PharmaceuticalsPhase 1
32
Lamotrigine ER tablet 50mgAlembic PharmaceuticalsPhase 1
32
Sonelokimab + SonelokimabMoonLake ImmunotherapeuticsPhase 1
28
GP30101 + Prezista® + GP30101 + Prezista®GEROPHARMPre-clinical
15
Metformin + Glucophage® + Metformin + Glucophage®GEROPHARMPhase 1
25
Metformine + Glucophage® Long + Metformin + Glucophage® LongGEROPHARMPhase 1
25
Humulin® Regular + Rinsulin® RGEROPHARMPre-clinical
15
Bosentan 125 mg + Tracleer 125Mg TabletGEROPHARMPhase 1
25
Rinsulin® mix 30/70 + Humulin® M3GEROPHARMPre-clinical
15
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
25
Clocortolone PivalateSun PharmaceuticalPhase 1
33
Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + PlaceboSun PharmaceuticalPhase 1
33
Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solutionJohnson & JohnsonPhase 1
33
SHR-1314Jiangsu Hengrui MedicinePhase 1
33
Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metforminAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
OmeprazoleAstraZenecaPhase 1
33
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)AstraZenecaPhase 1
33
D961S + Esomeprazole + Buffered acetylsalicylic acidAstraZenecaPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85